Concepedia

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

Kazuaki Chayama, Shoichi Takahashi, Joji Toyota, Yoshiyasu Karino, Kenji Ikeda, Hiroki Ishikawa, Hideaki Watanabe, Fiona McPhee, Eric Hughes, Hiromitsu Kumada

Hepatology · 2011 · 335 citations · 24 references

DOI

Abstract

Dual therapy with daclatasvir and asunaprevir, without Peg-IFN and RBV, can achieve high SVR rates in difficult-to-treat patients with HCV genotype 1b infection and previous null response to Peg-IFN and RBV.

References

24

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

Michael Fried, Mitchell L. Shiffman, K. Rajender Reddy et al. · New England Journal of Medicine · 2002 · 6.4K citations

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Michael P. Manns, John G. McHutchison, Stuart C. Gordon et al. · The Lancet · 2001 · 6K citations

, , +7

Diagnosis, management, and treatment of hepatitis C: An update # † ‡

Marc G. Ghany, Doris B. Strader, David L. Thomas et al. · Hepatology · 2008 · 3K citations · Full text

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

Fred Poordad, Jonathan McCone, Bruce R. Bacon et al. · New England Journal of Medicine · 2011 · 2.5K citations · Full text

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

Ira M. Jacobson, John G. McHutchison, Geoffrey Dusheiko et al. · New England Journal of Medicine · 2011 · 2.4K citations · Full text